AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 111 min read$RXRX

Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Se

Recursion Pharmaceuticals (RXRX) CEO Najat Khan sold 22,408 shares on 2026-09-08, retaining 2,072,890 shares. Over the past year, she sold 198,697 shares with no purchases. The company's stock traded at $3.52, with a market cap of $1.71 billion. GuruFocus values RXRX at $3.10, indicating fair valuation. Insider and guru activity shows caution, but clinical-stage status and pipeline success remain key for investors.

Original reporting
gurufocus.com
Published Sep 11, 2026, 4:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RXRX
Bearish
medium confidence
Mentioned
$RXRX
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$RXRXBearishLow
01

Why it matters

The CEO's recent share sale adds to a pattern of insider selling, which could be interpreted as cautionary but is modest in scale.

02

Market read

Primary insider sale provides a small, potentially bearish signal for RXRX investors.

03

What to watch

Recursion's valuation is near its GF Value, suggesting the stock is fairly priced despite the insider sell.

Relevance 5/10Novelty 5/10Timing: post‑sale on 2026-09-08

Background

Recursion Pharmaceuticals is a clinical‑stage biotech focused on AI‑driven drug discovery.

Company-level read

Ticker impact

$RXRXBearishMedium confidence
Context

CEO Najat Khan sold 22,408 shares on 2026-09-08, lowering his direct holding to 2,072,890 shares.

Expected impact

Potential modest downside of 2‑4% in the near term.

Evidence & confidence

The sale is a primary Form 4 disclosure, but the amount (~$80k) is relatively small for a mid‑cap biotech, limiting material impact.

Market effects

Sector

Minimal; insider activity does not materially affect the broader biotech sector.

Regional

None; the news is company‑specific.

Global

Low; limited to investors tracking Recursion.

Counterpoint

What could challenge this read

The sale may be routine personal liquidity and not indicative of company outlook.

Key entities

  • Executive
    Najat Khan

    CEO and President of Recursion Pharmaceuticals

Read at source← All news

Related articles

SEP 4
$RXRXMed

RXRX Stock Steadies As AI Drug Engine Tightens Spending

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

stockstotrade.com3 min
SEP 4
$RXRXMed

RXRX Tightens Cash Burn As AI Drug Pipeline Advances

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

stockstotrade.com4 min
SEP 4
$RXRXMed

RXRX Tightens Costs As AI Drug Pipeline Advances

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

timothysykes.com2 min
AUG 25
$RXRXMed

RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

stockstotrade.com3 min